1 Introduction
Celiac disease is an autoimmune disease that occurs in genetically susceptible individuals and progresses by intestinal inflammation.[1,2] [3] [4]
With gluten intake, gluten peptides bound to human leukocyte antigens and are recognized by T cells. T cells initiate the inflammatory process via T helper1 (Th1),[5] [6] [7] [1,8]
With the activation of T cells, Th1 and Th17 are synthesized, and, therefore, the level of proinflammatory cytokines increases. Tumor necrosis factor (TNF) subgroups are expected to increase via Th1 and interleukin 17 (IL 17) levels are expected to increase via Th17.
A TNF-like weak inducer of apoptosis (TWEAK), which is a cytokine from the TNF superfamily , shows its activity via the fibroblast growth factor-inducible 14 (Fn14) receptor.[9] [10] [11]
While IL 17 cytokine is synthesized by macrophages, natural killer T cells, dendritic cells, microglia, and neutrophils, it is also primarily synthesized by Th17.[12] [13]
Recent studies have frequently emphasized the role of sTWEAK and IL-17A in inflammatory and autoimmune diseases.[14,15] [3,16]
Therefore, in this study, we aimed to determine the sTWEAK and IL-17A levels in celiac patents and their association with the gluten diet and autoantibodies.
2 Methods
2.1 Study population
This study was conducted between April and August 2015 at the Turkey Yuksek Ihtisas Training and Research Hospital's Gastroenterology Clinic and the Ankara Numune Training and Research Hospital's Internal Medicine Clinic.
A total of 160 participants, 80 of whom were patients with celiac diagnosis and 80 of whom are healthy volunteers with no known diseases were included in this study.
The celiac group was made up of active patients and patients in remission who are under clinical supervision, over the age of 18, and with or without adherence to the diet. The patients who were non-compliant to a gluten-free diet and had clinical symptoms of stomachache, distension, diarrhea, and nausea, and the patients with high levels of C-reactive protein (CRP) at the laboratory were considered as the active celiac patients. The patients who had no symptoms, were compliant to the gluten-free diet, and had CRP levels within the normal limits were considered as celiac patients in remission. The patient group, which had a diet with no gluten for 3 months was considered as the patient group compliant to the gluten-free diet. Patients’ compliance to the diet was confirmed with clinical and laboratory findings.
The healthy control group was formed of healthy volunteers who applied to our hospital for a check-up and who had no known diseases or history of drug use. The healthy control group was included in the study based on their similarities to the patient group in age, gender, and body mass index (BMI) and in their order of application.
Patients who had known chronic illnesses, rheumatism or infective inflammatory diseases, acute liver or renal failure, thyroid dysfunction, or immunosuppressive drug use, and who were unsupervised were not included in the study.
The study was designed in accordance with the 2013 Brazil version of the Declaration of Helsinki. It was approved by the local Ethical Board Research Commission (date: June 18, 2014, protocol number: 320). Written consent was taken from all participants who were included in the study.
2.2 Biochemical parameters
Venous blood samples were taken from participants between the hours of 8 and 10 AM after 8 hours of fasting in order to measure laboratory parameters. The blood samples were then centrifuged for 10 minutes at 4000 rpm and separated. The serum samples were kept at −80 °C until all samples were collected. Later, laboratory parameters in all samples were examined during the same session.
The laboratory parameters, anti gliadin antibodies IgA (AGA-IgA), anti gliadin antibodies IgG (AGA-IgG), anti-tissue Transglutaminase IgA antibodies (Anti-t TGA), and anti-tissue Transglutaminase IgA antibodies (Anti-t TGG) were measured by electroilluminescence immunoassay method using Cobas e 601 (Roche Diagnostics Corp., Indianapolis, IN) analyzer. CRP was measured by immunoturbidimetric method using Hitachi Modular P800 (Roche Diagnostics Corp., Indianapolis, IN) analyzer. The erythrocyte and platelet count, leukocyte count, and other hemogram parameters were measured via the impedance (resistance) method using a Sysmex XE 2100 optic laser scatter hematology analyzer (Roche Diagnostic, Corp., Indianapolis, IN), and hemoglobin was quantified photometrically.
2.3 sTWEAK measurement
Soluble TNFs like weak inducer of apoptosis levels were measured by the serum enzyme-linked immunosorbent assay (ELISA) kit (eBioscience, Human TWEAK Instant ELISA, Cat no: BMS2006INST). The calculated overall intra-assay and inter-assay coefficient of variation was 7.9% to 9.2%. The results were expressed in pg/mL.
2.4 IL-17A measurement
Interleukin-17 levels were measured by the serum ELISA kit (BOSTER IMMUNOLEADER, human IL 17, Cat no: EK0430). The results were expressed in pg/mL.
2.5 Statistical analysis
The Statistical Package for Social Sciences (SPSS) for Windows 20 (IBM SPSS Inc., Chicago, MI) software was used for statistical assessments. The Kolmogorov–Smirnov test was utilized to determine the distribution of data. Continuous variables with normal distribution were expressed as mean ± standard deviation, and continuous variables without normal distribution were expressed as median [interquartile range]. Categorical variables were presented as numbers and percentage. Continuous variables with normal distribution were compared with an independent sample t -test where appropriate. Continuous variables with non-normal distribution were compared with the Mann–Whitney U test where appropriate. The relationship between the numeric parameters was analyzed by Pearson and Spearman correlation analysis. Other risk factors were adjusted with partial correlation and the association between AGA and anti-t TG antibodies, and sTWEAK and IL-17A levels were examined. A P value <0.05 was considered significant for statistical analyses.
3 Results
The demographic, characteristics, and laboratory findings of study population have been summarized in Table 1 . The study population was composed of 80 (24 men, 56 women, mean age: 44.6 ± 13.4 years) celiac patients and 80 (15 men, 65 women, mean age: 44.2 ± 14 years) healthy control group volunteers. A significant difference in terms of age, gender, and BMI levels were not determined in either group (P > 0.05). Smoking and alcohol use in both groups were similar (P > 0.05). In supervised celiac patients, the median duration of the disease was determined to be 6 years.
Table 1: The demographic characteristics and laboratory findings of the study population.
The mean creatinine level (0.6 ± 0.1 mg/dL vs. 0.8 ± 0.1 mg/dL, respectively; P = 0.021) was determined to be lower in celiac patients than the control group. The median alanine aminotransferase (21 IU/L vs. 18 IU/L, respectively; P = 0.003), aspartate aminotransferase (22 IU/L vs. 20 IU/L, respectively; P = 0.041), and CRP (2.5 mg/L vs. 1.2 mg/L, respectively; P = 0.031) levels and the mean total bilirubin (0.7 ± 0.3 mg/dL vs. 0.5 ± 0.3 mg/dL, respectively; P = 0.034) level were determined to be higher in celiac patients than the control group. A significant difference was not determined in terms of other biochemical and hemogram parameters (P > 0.05).
In celiac patients, the median IL-17A (117.5 pg/mL vs. 56.7 pg/mL, respectively; P = 0.001) was determined to be higher, and the median sTWEAK (543 pg/mL vs. 643 pg/mL, respectively; P = 0.016) level was determined to be lower, when compared with the control group (Fig. 1 ).
Figure 1: The distribution of sTWEAK and IL-17A levels between celiac patients and the control group. IL-17A = interleukin-17A, sTWEAK = soluble tumor necrosis factor like weak inducer of apoptosis.
In the celiac group, patients with adherence to the diet had a lower median IL-17A (98.1 pg/mL vs. 197.5 pg/mL, respectively; P = 0.034) level and a higher median sTWEAK (606 pg/mL vs. 522.8 pg/mL; P = 0.031) level than patients without adherence to the diet. IL-17A and sTWEAK levels based on the positivity or negativity of AGA (IgA and IgG) and anti-t TG (IgA and IgG) antibodies have been shown in detail in Table 2 .
Table 2: sTWEAK and IL-17A levels based on diet compliance and antibody positivity in celiac group.
In the patient group, the association between sTWEAK and IL-17A with celiac antibodies and other parameters has been shown in detail in Table 3 . A negative correlation was determined between the sTWEAK level and IL-17A (r = −0.567, P = 0.009) and CRP (r = −0.280, P = 0.012). A positive correlation was determined between IL-17A and CRP (r = 0.302, P = 0.013). A positive correlation between AGA-IgA and AGA-IgG levels and the IL-17A level, and a negative correlation with the sTWEAK level was determined. A negative correlation was determined between the anti-t TGA level and the sTWEAK (r = −0.282, P = 0.011) level. A positive correlation was determined between the anti-t TGG level and the IL-17A (r = 0.326, P = 0.003) level. The association between the sTWEAK and IL-17A levels and other parameters has been shown in detail in Table 3 .
Table 3: The association of sTWEAK and IL-17A with other parameters in celiac patients.
During the correlation analysis, when risk factors, other than celiac antibodies, associated with sTWEAK and IL-17A levels were cleared, it was determined that the association between the AGA (IgA and IgG) and anti-t TG (IgA and IgG) antibody levels and the sTWEAK and IL-17A levels continued (Table 4 ).
Table 4: The association between sTWEAK and IL-17A and antibody levels in celiac patients when other risk factors are adjusted.
4 Discussion
Our study has determined a lower sTWEAK level and a higher IL-17A level in celiac patients than in the control group. Regarding celiac patients, those with autoantibody-positive rather than autoantibody-negative and also patients following the gluten-free diet rather than those not adhering with the diet, had lower levels of sTWEAK and higher levels of IL-17A. The correlation analysis has shown that celiac antibodies are associated with these proinflammatory cytokines. As far as we are aware, this is the first study that examines the sTWEAK level in celiac patients.
Innate and acquired T-cell-mediated immune system plays an important role in celiac disease.[17] [18] [19] [20] TNF superfamily .
Soluble TNF like weak inducer of apoptosis is a member of the TNF superfamily , which can be associated with the pathogenesis of celiac disease. In many previous studies, it was thought that TWEAK could play a part in the pathogenesis of autoimmune/chronic inflammatory diseases.[21,22] [14]
Our study has found a lower sTWEAK level in celiac patients than in the control group. The sTWEAK level was also found to be lower in patients who did not adhere to the gluten diet, and who were autoantibody-positive than in patients who complied with the diet and who were antibody-negative. Furthermore, a negative correlation was determined among the AGA-IgA and the Anti-t TGA levels and the sTWEAK level. Previous studies have shown that inflammation is higher in patients who do not adhere to the diet and have high levels of autoantibodies.[17] [23] [24]
In our study, the IL-17A level was determined to be higher in celiac patients than in the control group. The IL-17A level was determined to be higher in patients who did not adhere to the gluten diet and who were autoantibody-positive than in patients who complied with the diet and who were antibody-negative. Furthermore, a positive correlation was determined between CRP and celiac antibodies and IL-17A. All of these results show that the increasing IL-17A level could be associated with the pathogenesis of celiac disease, which is an autoimmune/chronic disease. Previous studies that have examined the association between celiac patients and IL-17A have found a high level of IL-17A in celiac patients feeding on gluten, patients with villous atrophies in their mucosal biopsies and patients with positive autoantibody serology.[5,25–27]
A negative correlation was determined between sTWEAK and IL-17A and CRP. We can attribute this to the increase of IL-17A along with the increase of inflammation, and the decrease of the free form of sTWEAK, which is another increasing proinflammatory cytokine, by binding to the Fn14 receptor.[23]
The main limitation of our study is that our study is cross-sectional. Another limitation is the absence of a study on the Fn14 and CD 163 receptor levels along with sTWEAK levels in celiac patients. If the Fn14 and CD 163 receptors had been studied, we could determine more clearly the actual reason why the sTWEAK level in celiac patients was lower. Because, as we stated before, after acute inflammation starts, scavenger receptors and fn14 receptors rapidly increase and start to link to sTWEAK. Therefore, sTWEAK levels in serum start to decrease.
Lastly, another limitation is the celiac antibody levels in the control group not being studied. If we could attain data on the autoantibody levels of the control group, we could determine whether sTWEAK and IL-17A are independent risk factors for celiac disease. Because, in order to understand the presence of cytokines such as IL-17-A/sTWEAK in the inflammation pathogenesis of the celiac disease, different levels of cytokines, other than the control group, and their determinations as predictors of the disease are precious.
5 Conclusions
Consequently, sTWEAK and IL-17A levels were found to be different from the control group for celiac disease. For the subgroups consisting of celiac patients, the levels of these cytokines were coherent with gluten-free diet and different according to the autoantibody positivity. These conditions signify that sTWEAK and IL-17A may be correlated to the inflammation in celiac pathogenesis. In order to clearly understand the importance of sTWEAK and IL 17A in celiac pathogenesis, it is required to administer the anti-sTWEAK and anti-IL17-A treatments on active celiac patients and follow the clinical results.
References
1. Sjoberg V, Sandstrom O, Hedberg M, et al Intestinal T-cell responses in celiac disease—impact of celiac disease associated bacteria.
PloS ONE 2013; 8:e53414.
2. Sollid LM, Jabri B. Is celiac disease an autoimmune disorder?
Curr Opin Immunol 2005; 17:595–600.
3. Lahdenpera AI, Holtta V, Ruohtula T, et al Up-regulation of small intestinal interleukin-17 immunity in untreated coeliac disease but not in potential coeliac disease or in type 1 diabetes.
Clin Exp Immunol 2012; 167:226–234.
4. Xu H, Feely SL, Wang X, et al Gluten-sensitive enteropathy coincides with decreased capability of intestinal T cells to secrete IL-17 and IL-22 in a macaque model for celiac disease.
Clin Immunol 2013; 147:40–49.
5. Ortega C, Fernandez S, Estevez OA, et al IL-17 producing T cells in celiac disease: angels or devils?
Int Rev Immunol 2013; 32:534–543.
6. Abadie V, Discepolo V, Jabri B. Intraepithelial lymphocytes in celiac disease immunopathology.
Semin Immunopathol 2012; 34:551–566.
7. Garrote JA, Gomez-Gonzalez E, Bernardo D, et al Celiac disease pathogenesis: the proinflammatory cytokine network.
J Pediatr Gastroenterol Nutr 2008; 47 (suppl 1):S27–S32.
8. Di Sabatino A, Corazza GR. Coeliac disease.
Lancet 2009; 373:1480–1493.
9. Ates I, Ozkayar N, Akyel F, et al The relationship between asymptomatic organ damage, and serum soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) and Interleukin-17A (IL-17A) levels in non-diabetic hypertensive patients.
BMC Nephrol 2014; 15:159.
10. Brown SA, Ghosh A, Winkles JA. Full-length, membrane-anchored TWEAK can function as a juxtacrine signaling molecule and activate the NF-kappaB pathway.
J Biol Chem 2010; 285:17432–17441.
11. Wiley SR, Winkles JA. TWEAK, a member of the
TNF superfamily , is a multifunctional cytokine that binds the TweakR/Fn14 receptor.
Cytokine Growth Factor Rev 2003; 14:241–249.
12. Yamada H. Current perspectives on the role of IL-17 in autoimmune disease.
J Inflamm Res 2010; 3:33–44.
13. Maddur MS, Miossec P, Kaveri SV, et al Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies.
Am J Pathol 2012; 181:8–18.
14. Bertin D, Stephan D, Khrestchatisky M, Desplat-Jego S. Is TWEAK a biomarker for autoimmune/chronic inflammatory diseases?
Front Immunol 2013; 4:489.
15. Liang Y, Pan HF, Ye DQ. Tc17 cells in immunity and systemic autoimmunity.
Int Rev Immunol 2015; 34:318–331.
16. Medrano LM, Garcia-Magarinos M, Dema B, et al Th17-related genes and celiac disease susceptibility.
PLoS One 2012; 7:e31244.
17. Cicerone C, Nenna R, Pontone S. Th17, intestinal microbiota and the abnormal immune response in the pathogenesis of celiac disease.
Gastroenterol Hepatol Bed Bench 2015; 8:117–122.
18. Cua DJ, Tato CM. Innate IL-17-producing cells: the sentinels of the immune system.
Nat Rev Immunol 2010; 10:479–489.
19. Korn T, Bettelli E, Oukka M, et al IL-17 and Th17 Cells.
Annu Rev Immunol 2009; 27:485–517.
20. Castellanos-Rubio A, Santin I, Irastorza I, et al TH17 (and TH1) signatures of intestinal biopsies of CD patients in response to gliadin.
Autoimmunity 2009; 42:69–73.
21. Wisniacki N, Amaravadi L, Galluppi GR, et al Safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-TWEAK monoclonal antibody in patients with rheumatoid arthritis.
Clin Ther 2013; 35:1137–1149.
22. Schwartz N, Rubinstein T, Burkly LC, et al Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study.
Arthritis Res Ther 2009; 11:R143.
23. Vendrell J, Chacon MR. TWEAK: a new player in obesity and diabetes.
Front Immunol 2013; 4:488.
24. Moreno JA, Munoz-Garcia B, Martin-Ventura JL, et al The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis.
Atherosclerosis 2009; 207:103–110.
25. Monteleone I, Sarra M, Del Vecchio Blanco G, et al Characterization of IL-17A-producing cells in celiac disease mucosa.
J Immunol 2010; 184:2211–2218.
26. Bragde H, Jansson U, Jarlsfelt I, et al Gene expression profiling of duodenal biopsies discriminates celiac disease mucosa from normal mucosa.
Pediatr Res 2011; 69:530–537.
27. Caruso R, Marafini I, Del Vecchio Blanco G, et al Sampling of proximal and distal duodenal biopsies in the diagnosis and monitoring of celiac disease.
Dig Liver Dis 2014; 46:323–329.
